| Product | Indication | Dosage form | Strength |
|---|---|---|---|
| Vivifast® | Useful in the management of several types of cognitive disorders | Nov 2015 | |
| Viviflux® | Indicated for stroke primary and secondary prevention and for cerebrovascular disorders | Sep 2011 | |
| Vivimind® | Intended to protect memory and cognitive functions in MCI patients | Nov 2010 | |
| Zonisamide | Epilepsy | Hard capsules | 25, 50 and 100 mg |
| Zonisamide | Epilepsy | IR tablets | 25, 50, 100, 200 and 300 mg |
[*] Differentiated product
[**] Opioid
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.